Botanical Drug GM-XANTHO® Completes Phase I/IIa Trial for Atopic Dermatitis
Exhibitor: XANTHO BIOTECHNOLOGY CO., LTD.
Date: 2026-06-04
Booth No.: M434
Xanthon Bio is a botanical drug development company specializing in inflammatory skin diseases. Our R&D team has successfully extracted active ingredients from mangosteen to develop GM-XANTHO®, a topical cream that offers new hope to patients suffering from atopic dermatitis by effectively treating inflammation, itching, and redness. GM-XANTHO® has completed Phase I/IIa clinical trials in Taiwan, showing highly positive efficacy data and proving to be safe with no side effects for long-term use—a breakthrough alternative for those fearing steroid side effects. Having secured patents in the US, Europe, and Japan, we are now launching next-stage clinical trial plans in the US and Europe to drive global commercialization. At Bio Asia Taiwan, we are actively seeking partners for regional licensing or joint development to accelerate product launch and benefit patients worldwide.
More Exhibitor's Press Release
- Next Generations Therapy Manufacturing LEVITRONIX GMBH TAIWAN BRANCH / 2026-06-17
- The Fastest and Safest Depth Filtration LEVITRONIX GMBH TAIWAN BRANCH / 2026-06-17
- Highest Cell Viability in Perfusion LEVITRONIX GMBH TAIWAN BRANCH / 2026-06-17
- Wireless × Complete Recording × Traceability BrainChild DRS Powers Smarter Decisions BRAINCHILD ELECTRONIC CO., LTD. / 2026-06-16
- BrainChild PRV2.0 Precision Measurement Built for Accuracy, Reliability and Better Decisions BRAINCHILD ELECTRONIC CO., LTD. / 2026-06-16
- BrainChild XH13 Cloud Logger Delivers Environmental Visibility for Labs and Storage BRAINCHILD ELECTRONIC CO., LTD. / 2026-06-16
- Bridging the U.S. and Global Markets: EG BioMed Builds an International Precision Cancer Testing Ser EG BIOMED US INC. / 2026-06-15
- Blood-Based Early Cancer Detection: Advancing Precision Health Through DNA Methylation Science EG BIOMED US INC. / 2026-06-15
- EG BioMed U.S. CLIA/CAP-Certified Laboratory Opens Partnership Opportunities EG BIOMED US INC. / 2026-06-15
- 2026 BIO Asia: Next-Gen 3D Cell Culture & Exosome Solutions by LIS TECH & GeniCore Biotech LIS TECH CO., LTD. / 2026-06-04
- ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readines PROBIO TECHNOLOGY HK LIMITED. / 2026-06-04
- LIS TECH Showcases Regenerative Medicine and Bioprocessing Platform at BIO Asia–Taiwan 2026 LIS TECH CO., LTD. / 2026-06-03
- GeniCore Biotech Unveils Its AI-Powered Genimer™ Aptamer Platform LIS TECH CO., LTD. / 2026-06-03
- Medidata’s Digital Oversight Platform Empowers Pharma and CROs to Align with Next-Gen GCP MEDIDATA / 2026-06-02
- Medidata Powers Transformational Breakthroughs in Over 500 Global Clinical Trials with AI MEDIDATA / 2026-06-02
- Empowering eCOA to Deliver Flexible and Efficient Digital Solutions MEDIDATA / 2026-06-02
- Save the Date: LabWare Professional Seminar Coming This September! LABWARE TAIWAN CO., LTD. / 2026-05-29
- LabWare Named Best IT Solution at the Labmate Awards for Excellence 2025 LABWARE TAIWAN CO., LTD. / 2026-05-29
- SimTissue® by Lyson: The One-Stop Phantom Solution for Advanced Surgical Simulation LYSON MEDICAL TECHNOLOGY / 2026-05-27
- Top-Tier Laboratory Equipment Expert "Chuan Fu Technology" to Spark Innovation at BIO Asia-Taiwan CHUNG FU TECHNICAL DEVELOPMENT CO., LTD. / 2026-05-27
